Key result
In children with obesity, higher pre-treatment BMI and more metabolic comorbidities inversely predicted BMI SDS reduction during inpatient treatment, while pre-treatment leptin and adiponectin levels predicted post-treatment weight regain.
Why the study?
Dropouts and weight regain threaten inpatient pediatric obesity treatments, but the predictive role of clustered cardiometabolic comorbidities, leptin, and adiponectin was unclarified.
Do pre-treatment adipokines and metabolic risk factors predict dropouts and BMI SDS changes in children with obesity undergoing a 12-month inpatient weight loss program?
Cohort (n=144)
No
Do pre-treatment adipokines and metabolic risk factors predict dropouts and BMI SDS changes in children with obesity undergoing a 12-month inpatient weight loss program?
p-value: p=<0.001
Pre-treatment leptin and adiponectin levels, along with cardiometabolic comorbidities, predict post-treatment weight regain and dropout in children undergoing inpatient obesity treatment.
May inform risk stratification for pediatric obesity treatment; leaves open prospective validation before clinical adoption.
Background Inpatient pediatric obesity treatments are highly effective, although dropouts and weight regain threaten long-term results. Preliminary data indicate that leptin, adiponectin, and cardiometabolic comorbidities might predict treatment outcomes. Previous studies have mainly focused on the individual role of adipokines and comorbidities, which is counterintuitive, as these risk factors tend to cluster. This study aimed to predict the dropouts and treatment outcomes by pre-treatment patient characteristics extended with cardiometabolic comorbidities (individually and in total), leptin, and adiponectin. Methods Children aged 8–18 years were assessed before, immediately after and 6 months after a 12-month inpatient obesity treatment. Anthropometric data were collected at each visit. Pre-treatment lipid profiles; glucose, insulin, leptin, and adiponectin levels; and blood pressure were measured. The treatment outcome was evaluated by the change in body mass index (BMI) standard deviation score (SDS) corrected for age and sex. Results We recruited 144 children with a mean age of 14.3 ± 2.2 years and a mean BMI of 36.7 ± 6.2 kg/m 2 corresponding to 2.7 ± 0.4 BMI SDS. The 57 patients who dropped out during treatment and the 44 patients who dropped out during aftercare had a higher pre-treatment BMI compared to the patients who completed the treatment (mean BMI, 38.3 ± 6.8 kg/m 2 vs 35.7 ± 5.5 kg/m 2 ) and those who completed aftercare (mean BMI, 34.6 ± 5.3 kg/m 2 vs 37.7 ± 6.3 kg/m 2 ) (all p<0.05). Additionally, aftercare attenders were younger than non-attenders (mean age, 13.4 ± 2.3 years vs 14.9 ± 2.0, p<0.05). Patients lost on average 1.0 ± 0.4 SDS during treatment and regained 0.4 ± 0.3 SDS post-treatment corresponding to regain of 43 ± 27% (calculated as the increase in BMI SDS post-treatment over the BMI SDS lost during treatment). A higher BMI and more comorbidities inversely predicted BMI SDS reduction in linear regression (all p<0.05). The absolute BMI SDS increase after returning home was predicted by pre-treatment leptin and systolic blood pressure, whereas the post-treatment BMI SDS regain was predicted by pre-treatment age, leptin, and adiponectin levels (all p<0.05) in multivariate linear regressions. Conclusion Patients who need treatment the most are at increased risk for dropouts and weight regain, emphasizing the urgent need for interventions to reduce dropout and support inpatients after discharge. Furthermore, this study is the first to report that pre-treatment leptin and adiponectin levels predict post-treatment BMI SDS regain, requiring further research.
No takes yet. Share an insight, caveat, or question.
Vermeiren et al. (2022) conducted a cohort in Pediatric obesity (n=144). Pre-treatment patient characteristics, cardiometabolic comorbidities, and adipokines was evaluated on BMI SDS decrease during inpatient treatment (p=<0.001). In children with obesity, higher pre-treatment BMI and more metabolic comorbidities inversely predicted BMI SDS reduction during inpatient treatment, while pre-treatment leptin and adiponectin levels predicted post-treatment weight regain.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: